Healionics Announces Multi-Million Dollar STAR(TM) Biomaterial Supply Agreement with...

Healionics Announces Multi-Million Dollar STAR(TM) Biomaterial Supply Agreement with TR BioSurgical for Veterinary Glaucoma Implant

REDMOND, Wash.--(Business Wire)--
Healionics Corporation, a provider of next generation biomaterial
solutions to healthcare manufacturers, today announced that it has
entered into a multi-million dollar manufacturing, supply and
distribution agreement with TR BioSurgical, LLC (TRBIO) for use of its
flagship STAR(TM) biomaterial scaffold in a veterinary glaucoma
implant. Under this exclusive, multi-year agreement, Healionics will
provide its STAR biomaterial scaffold for TRBIO's TR-ClarifEYE, an
innovative implant for the treatment of glaucoma in animals, which is
planned for limited market launch in the first quarter of 2009.

"We are pleased that within two years of launching Healionics our
STAR--biomaterial that heals--will be used in its first commercial
product for helping pets, and we look forward to working with TRBIO on
additional veterinary ophthalmic device applications," said Michel
Alvarez, Chief Operating Officer and VP of Business Development of
Healionics. "The application of STAR in ophthalmic device implants for
humans is our next area of focus as it represents a significantly
larger market opportunity."

"TR-ClarifEYE has demonstrated promising results for canine
glaucoma, the leading cause of blindness in dogs," said Dr. Craig
Woods, CEO of TR BioSurgical, LLC. "This device has the potential to
help thousands of dogs each year and provide a substantial advancement
in veterinary ophthalmology."

TR-ClarifEYE is a surgically implanted veterinary device that
relieves the elevated ocular pressure accompanying glaucoma by
restoring outflow of intraocular fluid from the anterior chamber of
the eye to the surrounding vascular network. TR-ClarifEYE consists of
a special STAR silicone geometry that maintains appropriate drainage
by reducing fibrosis and consequent blockage of the flow.

Healionics' proprietary STAR--Sphere Templated Angiogenic
Regeneration--is a biomaterial scaffold designed to enhance
bio-integration and promote healing of implanted medical devices. In
addition to the veterinary ophthalmic market, Healionics currently has
numerous research agreements in place evaluating STAR biomaterial in
multiple market applications including human aesthetics, obesity,
diabetes, wound care, and infusion devices.

About TR BioSurgical, LLC

TR BioSurgical, LLC, founded in May 2007, is a veterinary
biomedical development company located in Chandler, Arizona. The
company was founded by a group of veterinarians, scientists and
business professionals to commercialize the most promising biomaterial
technologies for veterinary medicine. For more information about TR
BioSurgical, please visit http://www.trbio.com.

About Healionics Corporation

Healionics is a privately held biomaterials company whose mission
is to be the leading provider of tissue regeneration and device
biointegration solutions to healthcare manufacturers. Their flagship
STAR--Sphere Templated Angiogenic Regeneration--biomaterial scaffold
is a next generation solution for improving the performance of
implanted medical devices. Healionics Corporation is headquartered in
Redmond, Washington. For more information, please visit
http://www.healionics.com.

Rathbun Communications, Inc. for Healionics
Julie Rathbun, 206-769-9219
Julie@rathbuncomm.com

Copyright Business Wire 2008